CHINOOK THERAPEUTICS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash Flows from Operating Activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Reversal of non-cash consideration related to revenue
Depreciation and amortization expense
Loss (gain) on disposal of property and equipment
Amortization of finance lease right-of-use asset
Amortization of intangible assets
Impairment of property and equipment
Impairment of intangible assets
Non-cash lease expense
Non-cash operating lease expense
Stock-based compensation expense
Change in fair value of redeemable convertible preferred stock tranche liability
Change in fair value of contingent consideration and contingent value rights liabilities
Accretion of discounts and amortization of premiums on marketable securities
Realized gain on investments
Research and development expenses paid through issuance of common stock (including $150 to related party for the year ended December 31, 2019)
Financial advisory expenses paid through issuance of common stock
Deferred income taxes
Gain on sale of assets to equity method investment
Equity method investment gain (loss)

Changes in operating assets and liabilities:
Payment of contingent consideration
Accounts receivable
Income tax receivable
Prepaid expenses and other assets
Non-current assets
Accounts payable
Accrued and other liabilities
Long-term liabilities
Operating lease liabilities
Deferred revenue
Accrued clinical trial and manufacturing expenses

Net cash used in operating activities
Cash Flows from Investing Activities
Cash, cash equivalents and restricted cash acquired in connection with the Merger
Purchases of marketable securities
Proceeds from marketable securities
Purchases of property and equipment
Proceeds from sale of property and equipment
Net cash provided by (used in) investing activities
Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of offering costs
Proceeds from issuance of common stock pursuant to subscription agreements prior to Merger, net of offering costs
Proceeds from issuance of common stock pursuant to subscription agreements prior to Merger, net of issuance costs
Proceeds from issuance of common stock and accompanying pre-funded warrants in underwritten public offering, net of issuance costs
Proceeds from exercise of stock options and warrants and from Employee Stock Purchase Plan
Proceeds from at-the-market-sales agreement, net of issuance costs
Previously incurred issuance costs related to an underwritten public offering paid during period
Payment of contingent value rights liability
Proceeds from issuance of redeemable convertible preferred stock and related tranche rights, net of issuance costs
Proceeds from exercise of stock options
Proceeds from employee stock purchase plan
Repayment of finance lease liability
Net cash provided by financing activities
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental Cash Flow Information
Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities (related party)
Cash paid for amounts included in the measurement of lease liabilities

Supplemental Disclosure of Non-Cash Investing and Financing Activities
Purchases of property and equipment included in accounts payable and in accrued and other current liabilities
Operating lease right-of-use asset recorded on the adoption of ASC 842-related party
Right-of-use asset for office space acquired through leases
Issuance costs incurred but unpaid
Investment in equity securities acquired through non-cash consideration
Fair value of net assets acquired in Merger
Conversion of redeemable convertible stock to common stock upon closing of the Merger
Financial advisory expenses paid through issuance of common stock
Termination of redeemable convertible preferred stock tranche liability
Research and development expenses paid through issuance of common stock

Reconciliation of Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents
Restricted cash

Comments